Each dose increase tends to restore some degree of appetite suppression and metabolic benefit
Week 1: 0.6mg (0.2ml) once daily (20 units) Weeks 2: 1.2mg (0.4ml) once daily (40 units) Weeks 3: 1.8mg (0.6ml) once daily (60 units) Week 4: 2.8mg (0.8ml) once daily (80 units) Week 5 onwards: 3mg (1ml) once daily (100 units) (on-going maintenance dose) If patients can't tolerate a higher dose during dose escalation, the increase can be delayed by one more week
Important context: SURMOUNT-5 was an open-label trial funded by Eli Lilly, the manufacturer of tirzepatide
The STEP-1 trial found that Wegovy injections led to an average weight loss of around 17% over 68 weeks
If you are considering a compounded semaglutide product, consult a healthcare provider and only use a pharmacy they work with and trust
In Min6 cells, overexpression of MOTS-c downregulates basal levels and phosphorylation of mTORC1-related pathways in -cells (p-mTOR2448, p-4EBP-1 and p-P70S6K1), which is consistent with our previous report in T cells 7 (Fig
